Biogen (BIIB) EBITDA (2009 - 2026)

Biogen's EBITDA history runs 18 years deep, the most recent figure standing at -$283.3 million for Q1 2026.

• In Q1 2026, EBITDA rose 10.94% year-over-year to -$283.3 million; the TTM figure through Mar 2026 stood at -$812.9 million (down 26.01% YoY), while the FY2025 annual figure was -$847.7 million, down 109.62% from the prior year.
• EBITDA was -$283.3 million for Q1 2026 at Biogen, up from -$551.5 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $901.6 million in Q3 2022 to a low of -$800.8 million in Q3 2023.
• Historically, EBITDA has averaged $24.7 million across 5 years, with a median of -$77.4 million in 2024.
• Biggest YoY gain for EBITDA was 76.56% in 2024; the steepest drop was 328.84% in 2024.
• A 5-year view of EBITDA shows it stood at $439.8 million in 2022, then tumbled by 70.99% to $127.6 million in 2023, then plunged by 328.84% to -$292.0 million in 2024, then tumbled by 88.87% to -$551.5 million in 2025, then surged by 48.63% to -$283.3 million in 2026.
• The last three EBITDA figures came in at -$283.3 million (Q1 2026), -$551.5 million (Q4 2025), and -$117.1 million (Q3 2025), per Business Quant data.